Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.
Stahler A, Karthaus M, Fruehauf S, Graeven U, Müller L, Fischer von Weikersthal L, Caca K, Goekkurt E, Ballhausen A, Sommerhäuser G, Alig AHS, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T, Modest DP. Stahler A, et al. Among authors: muller l. EClinicalMedicine. 2024 Dec 16;79:103004. doi: 10.1016/j.eclinm.2024.103004. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39802302 Free PMC article.
Impaired macroscopic CSF flow by sevoflurane in humans - both during and after anesthesia.
Zimmermann J, Sorg C, Müller L, Zistler F, Neumaier V, Bonhoeffer M, Ranft A, Golkowski D, Priller J, Zimmer C, Ilg R, Preibisch C, Schneider G, Nuttall R, Zott B. Zimmermann J, et al. Among authors: muller l. Anesthesiology. 2025 Jan 8. doi: 10.1097/ALN.0000000000005360. Online ahead of print. Anesthesiology. 2025. PMID: 39786916
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, Löwer M, Müller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lörks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kröner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, Türeci Ö, Camidge DR. Lopez J, et al. Among authors: muller l. Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03334-7. Online ahead of print. Nat Med. 2025. PMID: 39762422
2,626 results